Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced plans to initiate a Phase 2 clinical trial for TNX-2900 in 2026 to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE